A week and a half after learning that Eli Lilly was ending a joint project to develop inhaled insulin, Alkermes (NASDAQ: ALKS) is cutting some 150 jobs and closing a manufacturing plant, the Cambridge, MA-based firm announced today. The job cuts represent a reduction of about 18 percent in the firm’s staff.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
